Presenting Risks and Benefits Clearly to Clinical Trial Participants

Introduction: The Importance of Risk-Benefit Disclosure

Transparency in presenting risks and benefits is a critical component of informed consent in clinical trials. Participants must fully understand what they are agreeing to, and regulatory bodies such as the FDA, EMA, and ICH-GCP emphasize clarity, accuracy, and balance in disclosure. Misrepresentation or omission of risks can compromise trial integrity, lead to ethical violations, and even result in regulatory penalties. Conversely, overstating benefits may create undue expectations, which can influence decision-making and reduce trust.

This tutorial provides practical, step-by-step guidance for clinical trial professionals on how to present risks and benefits transparently in informed consent forms (ICFs) and during discussions with participants.

Regulatory Expectations: What Must Be Disclosed

ICH-GCP section 4.8 requires investigators to provide a comprehensive explanation of potential risks and benefits to participants. Regulators mandate that disclosure must be:

• Complete – All known and reasonably foreseeable risks must be explained
• Balanced – Benefits must not be exaggerated and should be stated realistically
• Understandable – Language must be accessible to participants, avoiding jargon
• Ongoing – Updates must be shared as new safety information emerges

For example, if hepatotoxicity risk emerges during an oncology trial, the ICF must be updated, and participants re-consented.

Strategies for Communicating Risks

Risk communication should be tailored for participant comprehension. Key strategies include:

• ➤ Use plain language to describe medical terms (e.g., “liver damage” instead of “hepatotoxicity”)
• ➤ Quantify risks using frequencies (“1 in 100 participants may experience…”) rather than vague terms like “rare”
• ➤ Include both common and serious risks, clearly differentiating between them
• ➤ Avoid minimizing risks with reassuring language that could undermine objectivity

Visual aids such as bar graphs or pictograms can also be highly effective in helping participants grasp relative risk levels.

Strategies for Communicating Benefits

While benefits must be presented to ensure balance, they should not be overstated. ICH-GCP requires that benefits be framed realistically:

• Clarify whether benefits are direct (participant health improvement) or indirect (contribution to science)
• Avoid guaranteeing therapeutic benefit in early-phase studies
• Provide sample outcomes from past trials where relevant, but note uncertainties

For example, in an investigational vaccine trial, the benefit may be described as “potential protection against disease if the vaccine proves effective,” not as “this vaccine will protect you.”

Sample Risk-Benefit Table for Consent Forms

Case Study: Miscommunication in Risk Disclosure

In a cardiovascular trial in 2019, regulators identified that the consent form listed “possible side effects” but failed to specify the frequency of arrhythmia events, which had already been observed in Phase II studies. This omission led to an FDA Form 483 observation, requiring immediate re-consent of participants and training of site staff on risk communication.

This case highlights the regulatory expectation that both the nature and likelihood of risks must be disclosed in clear and quantifiable terms.

Checklist for Transparent Risk-Benefit Disclosure

• Are all foreseeable risks clearly listed?
• Are risks quantified rather than described vaguely?
• Are potential benefits described realistically?
• Is the language understandable to a lay audience?
• Is there a process for updating participants on new risks?

External Resources

Professionals can access guidance on transparent disclosure from regulatory agencies and trial registries. For instance, the NIHR’s Be Part of Research platform offers resources on how risks and benefits should be communicated in ongoing studies.

Conclusion: Building Trust Through Transparency

Clear, accurate, and balanced disclosure of risks and benefits is both a regulatory requirement and an ethical obligation. Transparent communication empowers participants to make informed choices, strengthens trial credibility, and ensures compliance with ICH-GCP and global regulations. By using structured communication strategies, visual tools, and ongoing updates, sponsors and investigators can uphold participant rights and foster long-term trust in clinical research.

How Ethics Committees Balance Scientific Value and Risk to Participants

Introduction: Ethical Obligation to Weigh Science Against Risk

One of the core responsibilities of Ethics Committees (ECs) is to ensure that the risks posed to participants in a clinical trial are justified by the potential scientific and social value of the research. This concept, embedded in ICH-GCP and national regulations worldwide, is central to ethical trial conduct. An ethically sound trial must demonstrate that it is scientifically necessary, methodologically valid, and poses no more than minimal or justifiable risk to participants.

From oncology studies with invasive interventions to first-in-human trials, the balancing act between research benefit and participant exposure is nuanced and critical. Ethics Committees must navigate complex data, sponsor claims, and participant protections to uphold ethical standards in research.

1. The Principle of Proportionality in Ethical Review

The principle of proportionality requires that the greater the risks involved in a trial, the higher the threshold for scientific and ethical justification. ECs apply this principle during protocol assessment by asking:

• Does the study address a meaningful clinical or scientific question?
• Is the methodology robust enough to yield valid results?
• Are safer alternative study designs available?

Trials involving placebo-controlled groups in serious illnesses must show equipoise — genuine uncertainty in the medical community — about the intervention’s effectiveness.

2. Evaluating Scientific Merit of the Study

Scientific merit is the foundation upon which ethical acceptability is built. An EC must examine:

• Study rationale and background literature
• Appropriateness of endpoints and statistical analysis
• Feasibility of recruitment and sample size justification

For example, a trial proposing 200 patients to test a new asthma inhaler must show existing preclinical and phase I safety data, and justify why placebo is ethically acceptable for a control group.

3. Defining and Assessing Risk Types

Ethics Committees categorize and assess different types of risk:

• Physical risk: Adverse effects, invasive procedures, hospitalization
• Psychological risk: Emotional stress, anxiety, depression
• Social risk: Stigmatization, loss of privacy, discrimination
• Legal risk: Reporting to law enforcement or government agencies
• Financial risk: Cost of treatment-related complications

Each risk must be described, mitigated, and justified in the protocol. ECs often request risk tables mapping each procedure to potential harms and mitigation strategies.

4. Risk Mitigation and Monitoring Strategies

Ethics Committees look for active risk minimization measures, including:

• Stopping rules and interim analysis plans
• Availability of rescue medication and emergency care
• Frequent safety lab assessments
• Dedicated Data Safety Monitoring Boards (DSMBs)
• Insurance coverage for trial-related injuries

In early-phase oncology trials, sponsors often include 24/7 medical monitoring and rapid reporting pathways for SAEs to ensure risk containment.

5. Assessing Benefit to Individual Participants

While many trials may not offer direct benefit, ECs assess whether:

• Participants may gain therapeutic access to investigational products
• Monitoring may identify unrelated medical issues early
• The knowledge gained could benefit the participant’s community or demographic

For example, a diabetes prevention study among Indigenous populations may provide targeted health education, dietary interventions, and long-term health monitoring, which indirectly benefits participants.

6. Inclusion of Vulnerable Populations and Heightened Ethical Scrutiny

When vulnerable subjects are involved, ECs must apply stricter criteria. This includes assessing:

• Whether the research cannot be done in non-vulnerable populations
• Whether risk levels are minimal or justified by direct benefit
• Whether consent procedures are appropriately adapted

Trials involving children or those with cognitive impairments often include independent ethics monitors to observe consent and monitoring processes.

7. Post-Trial Access and Long-Term Benefit Considerations

Ethics Committees increasingly ask whether successful interventions will be accessible after the trial ends. Key questions include:

• Will participants continue to receive treatment?
• Is the drug affordable and available in the trial region?
• Has the sponsor committed to access plans or donation programs?

In rare disease trials, post-trial access is often a primary ethical concern, especially when no alternatives exist.

8. Documenting Risk-Benefit Assessments in EC Minutes

ECs must transparently record how the balance of risks and benefits was determined. Documentation includes:

• Rationale for accepting specific risks
• Recommendations for protocol modifications
• Conditions for approval based on ongoing safety review

This record forms the ethical foundation for trial conduct and future inspections or audits.

Conclusion: A Dynamic and Contextual Judgment

Balancing scientific value with participant risk is not a fixed calculation—it evolves as more data become available, the study progresses, and the risk landscape shifts. Ethics Committees must remain engaged throughout the trial, reassessing this balance and adapting oversight accordingly.

By following regulatory frameworks, institutional SOPs, and global ethical principles, ECs can ensure that research advances without compromising the rights, dignity, and safety of its participants.